Healios KKHLOSF 57 Buyback Yield % is -25.56 as of Jul. 05, 2026. GuruFocus rates HLOSF with a GF Score™ of 57/100 and a GF Value™ of $0.41 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 741 Biotechnology companies, Healios KK ranks worse than 73.41% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Healios KK's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLOSF vs VRTX, REGN, ALNY: Buyback Yield % Comparison
For the Biotechnology subindustry, Healios KK's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Healios KK Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Healios KK's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Healios KK's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Healios KK (HLOSF) has a Buyback Yield % of -25.56 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Healios KK and its competitors. According to the industry distribution chart, Healios KK ranks #544 out of 741 companies in the Biotechnology industry, placing it in the top 73.4%.
Is Healios KK's Buyback Yield % too high?
Healios KK's current Buyback Yield % is -25.56. Based on the distribution chart, Healios KK ranks #544 out of 741 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Healios KK has a GF Score™ of 57/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Healios KK's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Healios KK ranks #544 out of 741 companies for Buyback Yield %. This places Healios KK in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Healios KK and its competitors. Healios KK's current Buyback Yield % is -25.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healios KK stock overvalued right now?
Based on GuruFocus' analysis, Healios KK (HLOSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.41, compared to a current price of $1.80 — trading 339% above its estimated fair value. The current Buyback Yield % is -25.56. Healios KK's overall GF Score™ is 57/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Healios KK (HLOSF), the current Buyback Yield % is -25.56 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Healios KK (HLOSF) Overvalued in 2026?
Based on GuruFocus' analysis, Healios KK stock appears to be overvalued.
The current stock price of $1.80 is trading 339% above its estimated GF Value™ of $0.41.
GuruFocus considers Healios KK to be Significantly Overvalued.
Key valuation signals for HLOSF:
Buyback Yield %: -25.56
GF Value™: $0.41 vs. price of $1.80 (339% above fair value)
No single metric tells the full story. See the HLOSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Healios KK is involved in development and sales of opthalmological surgery adjuvants and research, development and manufacture of cell therapy products and regenerative medicine products. The company is developing treatments for age-related macular degeneration and organ anlage transplantation therapy. The company develops next-generation cell therapies using a proprietary gene-edited induced pluripotent stem cell (iPSC) platform, with programs targeting immuno-oncology, ophthalmology, liver diseases, ischemic stroke, and acute respiratory distress syndrome.
57GF Score
Get the complete analysis for HLOSF
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HLOSF has been successfully added to your 
